Several studies have suggested that pathologic complete response was not particularly prognostic for ER+, HER2+ breast cancers, suggesting the possibility that a subset of HER2+, ER+ breast cancers are driven primarily by ER, and biologically behave more like HER2−, ER+ breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.